REN and coronary artery disorder: Our aim in this study is to use a DCE to evaluate the stated patient preferences for the branded and generic forms of the four classes of medications that are frequently used for the secondary prevention of CHD: statins, beta-blockers, renin–angiotensin–aldosterone-system blockers (RAAS blockers), and aspirin, in a cohort of patients with national insurance.